Anthropic IPO Explained: ANT Stock, Valuation and the Risks Behind Claude
Anthropic is preparing to list as ANT. Its IPO filing reveals explosive growth, unusual voting rights and vast compute commitments, while price and offering size remain unset.
Follow the breakthroughs and disruptions driving the technology industry. From artificial intelligence and advanced chips to new digital platforms and corporate strategies, this section covers how leading tech companies innovate and shape the future of business. We highlight major product launches, research advances and market moves to give readers a clear view of where technology and commerce intersect.
Anthropic’s IPO filing values about $6.2 billion of note principal at $108.6 billion, highlighting non-cash losses and dilution rather than hidden expenses.
Microsoft revenue has risen almost 57% since fiscal 2023 while headcount is broadly flat, putting AI demand, job cuts and infrastructure costs in focus.
Nvidia plans a $3 billion Meta investment as their Muse partnership expands and Meta prices $37.5 billion in equity offerings to support its AI buildout.
OpenAI launches GPT-6.1 Terra at $1 per million input tokens and $5 per million output tokens, targeting cheaper computer use, coding and business automation.
Microsoft opens voluntary buyouts to about 60,000 eligible employees as AI spending grows, with departures and savings still uncertain ahead of earnings.
Anthropic’s reported $100 billion IPO ambition could top SpaceX’s record, while its filing reveals computing agreements worth up to $120.5 billion with SpaceXAI.
Anthropic files for a Nasdaq IPO under ANT, disclosing $16.3 billion in first-half revenue, an $80.7 billion net loss and extensive computing obligations.
Oracle expands AI Agent Studio into industry applications as ORCL investors weigh software growth, a planned US rollout and the cost of its AI buildout.
Anthropic reportedly planned an October 26 public S-1 filing ahead of a November IPO, with a firm listing date and offering terms still unconfirmed.